Deuterium exchange and mass spectrometry reveal the interaction differences of two synthetic modulators of RXRα LBD

Protein amide hydrogen/deuterium (H/D) exchange was used to compare the interactions of two antagonists, UVI 2112 and UVI 3003, with that of the agonist, 9‐cis‐retinoic acid, upon binding to the human retinoid X receptor alpha ligand‐binding domain (hRXRα LBD) homodimer. Analysis of the H/D content by mass spectrometry showed that in comparison to 9‐cis‐retinoic acid, the antagonists provide much greater protection toward deuterium exchange‐in throughout the protein, suggesting that the protein–antagonist complex adopts a more restricted conformation or ensemble of conformations in which solvent accesses to amide protons are reduced. A comparison between the two antagonists shows that UVI 3003 is more protective in the C‐terminal region due to the extra hydrophobic interactions derived from the atoms in the benzene ring of the carboxylic acid chain. It was less protective within regions comprising peptides 271–278 and 326–330 due to differences in conformational orientation, and/or shorter carboxylic acid chain length. Decreased deuterium exchange‐in in the segment 234–239 where the residues do not involve interactions with the ligand was observed with the two antagonists, but not with 9‐cis‐RA. The amide protons of helix 12 of the agonist‐ or antagonist‐occupied protein in solution have the same deuterium exchange rates as the unliganded protein, supporting a suggestion made previously that helix 12 can cover the occupied binding cavity only with the cofactor present to adjust its location.

[1]  W. Ellmeier,et al.  Down-regulation of RXRalpha expression is essential for neutrophil development from granulocyte/monocyte progenitors. , 2007, Blood.

[2]  M. Deinzer,et al.  Investigation of ligand interactions with human RXRα by hydrogen/deuterium exchange and mass spectrometry , 2006, Journal of the American Society for Mass Spectrometry.

[3]  A. Itai,et al.  A new RXR agonist, HX630, suppresses intimal hyperplasia in a mouse blood flow cessation model. , 2006, Journal of molecular and cellular cardiology.

[4]  I. Ho,et al.  Cutting Edge: Inhibition of the Retinoid X Receptor (RXR) Blocks T Helper 2 Differentiation and Prevents Allergic Lung Inflammation , 2006, The Journal of Immunology.

[5]  L. Altucci,et al.  Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. , 2005, Cancer research.

[6]  V. Vivat-Hannah,et al.  Retinoids as therapeutic agents: today and tomorrow. , 2005, Mini reviews in medicinal chemistry.

[7]  Paul Webb,et al.  Conformational adaptation of nuclear receptor ligand binding domains to agonists: Potential for novel approaches to ligand design , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  K. Hede Rexinoids may be ready for prime time in prevention, but challenges remain. , 2004, Journal of the National Cancer Institute.

[9]  A. Szántó,et al.  Retinoid X receptors: X-ploring their (patho)physiological functions , 2004, Cell Death and Differentiation.

[10]  H. Xu,et al.  Structure-based design of potent retinoid X receptor alpha agonists. , 2004, Journal of medicinal chemistry.

[11]  F. Villarroya,et al.  Retinoids and retinoid receptors in the control of energy balance: novel pharmacological strategies in obesity and diabetes. , 2004, Current medicinal chemistry.

[12]  M. Deinzer,et al.  Dynamics and ligand-induced solvent accessibility changes in human retinoid X receptor homodimer determined by hydrogen deuterium exchange and mass spectrometry. , 2004, Biochemistry.

[13]  R. Evans,et al.  The Structural Basis for the Specificity of Retinoid-X Receptor-selective Agonists: New Insights Into the Role of Helix H12* , 2002, The Journal of Biological Chemistry.

[14]  Neil J. McKenna,et al.  Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.

[15]  Millard H. Lambert,et al.  Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα , 2002, Nature.

[16]  Hai Pan,et al.  Hydrogen Exchange-Mass Spectrometry , 2002, Molecular & Cellular Proteomics.

[17]  S. Dakoji,et al.  Studies on the inactivation of bovine liver enoyl-CoA hydratase by (methylenecyclopropyl)formyl-CoA: elucidation of the inactivation mechanism and identification of cysteine-114 as the entrapped nucleophile. , 2001, Journal of the American Chemical Society.

[18]  F. Rastinejad Retinoid X receptor and its partners in the nuclear receptor family. , 2001, Current opinion in structural biology.

[19]  L. Hamann An Efficient, Stereospecific Synthesis of the Dimer‐Selective Retinoid X Receptor Modulator (2E,4E,6Z)‐7‐ [5,6,7,8‐Tetrahydro‐5,5,8,8‐tetramethyl‐2‐(n‐propyloxy)naphthalen‐3‐yl] ‐3‐methylocta‐2,4,6‐trienoic Acid. , 2000 .

[20]  L. Hamann An efficient, stereospecific synthesis of the dimer-selective retinoid X receptor modulator (2E,4E,6Z)-7-[5,6,7,8- tetrahydro-5,5, 8,8-tetramethyl-2-(n-propyloxy)naphthalen-3-yl]-3-methyl octa-2,4, 6-trienoic acid. , 2000, The Journal of organic chemistry.

[21]  L. Freedman Increasing the Complexity of Coactivation in Nuclear Receptor Signaling , 1999, Cell.

[22]  Jaime Prilusky,et al.  Automated analysis of interatomic contacts in proteins , 1999, Bioinform..

[23]  L. Hamann,et al.  Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists , 1997, Nature.

[24]  L. Dardashti,et al.  Identification of the first retinoid X, receptor homodimer antagonist. , 1996, Journal of medicinal chemistry.

[25]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[26]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[27]  J. Thornton,et al.  Satisfying hydrogen bonding potential in proteins. , 1994, Journal of molecular biology.

[28]  G. Vriend,et al.  The use of in vitro peptide binding profiles and in silico ligand-receptor interaction profiles to describe ligand-induced conformations of the retinoid X receptor alpha ligand-binding domain. , 2007, Molecular endocrinology.

[29]  L Nagy,et al.  The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. , 2003, Journal of biological regulators and homeostatic agents.

[30]  D. D. Perrin,et al.  Purification of Laboratory Chemicals , 2022 .